11 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Sep 2030
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends May 2037 · High confidence
Also notable
Ends Nov 2042 · Medium confidence
Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof
US 11,840,559
Granted 2023. Computed term ends 2037. A terminal disclaimer caps this term to an earlier patent's.
Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof
US 12,350,320
A family of 8 related applications built on the 2025 grant. Too new for citation comparison; protection runs to 2042.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 12, 2027The maintenance fee for Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof (US 11,840,559) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions Comprising Pharmaceutically Acceptable Salts of Glucagon-Like PEPTIDE-1 Analogs and Uses Thereof | 5 in force | to Nov 2042 |
| Human Amylin Analog Polypeptides and Methods of Use | 2 in force | to Feb 2042 |
| Long Acting Glucagon Like POLYPEPTIDE-1 (GLP-1) Receptor Agonists and Methods of Use | 1 in force | to Dec 2041 |
| Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs and Methods of Use | 1 in force | to Apr 2041 |
| Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof | 1 in force | to May 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,042,557 | Rapid Establishment And/Or Termination of Substantial Steady-State Drug Delivery In force · High confidence | In force | High confidence | |
| US 11,840,559 | Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,540,168 | Human Amylin Analog Polypeptides and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,122,816 | Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 12,084,485 | Long Acting Glucagon Like POLYPEPTIDE-1 (GLP-1) Receptor Agonists and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,018,059 | Human Amylin Analog Polypeptides and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,233,110 | Compositions Comprising Pharmaceutically Acceptable Salts of Glucagon-Like PEPTIDE-1 Analogs and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,233,111 | Compositions Comprising Pharmaceutically Acceptable Salts of Glucagon-Like PEPTIDE-1 Analogs and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,233,112 | Compositions Comprising Pharmaceutically Acceptable Salts of Amylin Analogs and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,337,029 | Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 11: 9 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
7 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.